Webcast Keryx Biopharmaceuticals, Inc. at Biotechnology Industry Organization CEO & Investor Conference (Live) 02/09/10 at 2:00 p.m. ET

Receive E-mail Alerts

|

RSS Feeds

Keyword Search

2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004

Date Title   02/03/10 Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer 02/02/10 Keryx Biopharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference 01/29/10 Keryx Biopharmaceuticals Announces Positive Phase 2 Study Results of Perifosine as a Single Agent for the Treatment of Advanced Waldenstrom's Macroglobulinemia 01/27/10 Keryx Biopharmaceuticals, Inc. to Conduct Conference Call to Discuss KRX-0401 (Perifosine) Clinical Development Program in Colorectal Cancer 01/25/10 Keryx Reports Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 01/21/10 Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the ASCO 2010 Gastrointestinal Cancers Symposium 01/07/10 Keryx Biopharmaceuticals to Present at the J.P. Morgan 28th Annual Healthcare Conference 01/05/10 Keryx Biopharmaceuticals Announces Special Protocol Assessment Agreement with FDA for Phase 3 Registration Program of Zerenex in the Treatment of Hyperphosphatemia